News Vertex Pharmaceuticals Incorporated Sao Paulo

Stocks

VRTX34

BRVRTXBDR001

Pharmaceuticals

Market Closed - Sao Paulo 14:59:44 2026-10-28 EDT			5-day change	1st Jan Change
88.32 ^BRL	+1.47%		+11.29%	+12.88%

10-28	ConvaTec to Spend GBP500 Million on New Global R&D Hub in Manchester, England, Over Next Decade	MT
10-23	Vertex Pharmaceuticals Incorporated Presents at American Society of Nephrology Kidney Week 2026, Oct-23-2026 06:15 PM

All News

Mentions Relevance

10-23	Vertex Pharmaceuticals Incorporated Presents at American Society of Nephrology Kidney Week 2026, Oct-23-2026 06:15 PM
10-23	Vertex Pharmaceuticals Incorporated Publishes Phase 3 RAINIER Results For Povetacicept In IgA Nephropathy And Advances Povetacicept Clinical Research Program In IgAN	CI
10-23	Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026	BU
10-20	Vertex Pharmaceuticals Incorporated Announces Appointment of Daniel Brennan as Member of the Board of Directors, Audit and Finance Committee	CI
10-20	Vertex Appoints Daniel Brennan to its Board of Directors	BU
10-15	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
10-09	Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children	MT
10-09	Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference	BU
10-09	Vertex Pharmaceuticals Incorporated Presents New Interim Data on Alyftrek in Children Ages 2 to 5 Years At the North American Cystic Fibrosis Conference	CI
10-08	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
10-07	Vertex to Announce Third Quarter 2026 Financial Results November 2nd	BU
10-07	Vertex Pharmaceuticals Incorporated Presents at Bank of America Global Healthcare Conference 2026, Sep-23-2026 09:05 AM
09-28	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
09-23	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
09-22	Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2b AMPLIFIED Study Of Inaxaplin And Completes Enrollment In The Phase 2/3 AMPLITUDE Trial	CI
09-22	Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial	MT
09-22	Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial	BU
09-15	Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain	BU
09-14	Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM
09-10	Vertex Pharmaceuticals Incorporated Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM
09-10	Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 04:30 PM
09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
09-01	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027	CI
09-01	Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027	CI